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Abstract
IL-21 is a pleiotropic cytokine that is required for normal immunoglobulin production. We previously
showed that IL-21 was elevated in BXSB-Yaa mice with systemic lupus erythematosus. These mice
also have elevated IL-10 levels, and we now show that IL-21 induces IL-10 mRNA and protein,
suggesting unexpected immunosuppressive activities for IL-21. Indeed, Th1 priming with IL-21
leads to accumulation of cells with immunosuppressive activity, and IL-21 over-expression decreases
specific antibody production after immunization in an IL-10-dependent fashion. Moreover, we show
that IL-21 signaling is required for maximal induction of IL-10 by IL-6 or IL-27. Overall, our data
indicate that IL-21 regulates immune responses at least in part by inducing IL-10 and reveal
unanticipated immunosuppressive actions for this cytokine.
Introduction
T cell differentiation is a highly regulated event, leading to the production of committed effector
cells that mediate the elimination of a broad range of pathogens. Three major T cell effector
lineages have been described thus far: the Th1, Th2 and Th17 lineages. The differentiation of
each of these is controlled in part by lineage-specific transcription factors that orchestrate and
reinforce specific effector programs (1,2), with each of these T cell populations producing a
characteristic array of cytokines that mediate effector function not only of T cells but also of
B cells and antigen-presenting cells.
Regulatory mechanisms have evolved to limit the functional activity of these effector T cells.
Some of these involve specialized regulatory subsets comprising both natural and induced T
regulatory cells (3). Additionally, each of these T cell lineages is also capable of self-regulation.
IL-10 is a central cytokine involved in this process, suppressing the production of inflammatory
cytokines and inhibiting the function of antigen-presenting cells, thereby diminishing T cell
responses to antigen (4). Thus, IL-10 is a critical negative regulator of a range of
pathophysiological responses. Although its production from T cells was initially reported to
be restricted to the Th2 lineage, it is now clear that IL-10 is also produced by Th1 and Th17
cells and that it can limit the inflammatory effector responses of these cells (5,6), underscoring
the importance of understanding the mechanisms for controlling IL-10 production in these
effector populations.
IL-21 is a type I cytokine that is produced by antigen-stimulated CD4+ T cells as well as NK
T cells, but its target populations include both lymphoid and non-lymphoid populations,
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including T, B, NK, and myeloid cells (7). IL-21 signals through a heterodimeric receptor
containing IL-21R (8,9) plus the common cytokine receptor γ chain, γc (7,10,11), which is
mutated in humans with X-linked severe combined immunodeficiency (12) and also is shared
by the receptors for IL-2, IL-4, IL-7, IL-9, and IL-15 (13). Like IL-10, expression of IL-21 was
initially reported to be Th2 specific (14), but subsequent studies demonstrated that IL-21 is
also produced by Th1, Th2, and Th17 CD4+ T cell subsets, thus having the potential to act as
an immunoregulatory cytokine in the context of each of these effector populations (15-19).
Although the role of IL-21 in the differentiation of Th17 cells remains controversial (20,21),
it is clear that IL-21 can enhance the expansion of these cells via the induction of IL-23R on
Th17 cells (15).
IL-21 can potently augment both humoral and cell-mediated immunity, but it also has inhibitory
effects. IL-21 is known to critically regulate immunoglobulin production (22) and to drive the
differentiation of B cells to antibody-producing plasma cells (23,24). At least part of this effect
of IL-21 on immunoglobulin production involves its role in the development of T follicular
helper cells that drive germinal center development (25,26). Moreover, IL-21 can cooperate
with IL-7 or IL-15 to promote CD8+ T cell expansion (27), and it promotes anti-tumor
responses by CD8+ T cells and NK cells (27-31). Conversely, IL-21 exerts negative effects on
lymphoid and myeloid cells, inducing B-cell apoptosis (24,32,33) and inhibiting dendritic cell
maturation and function (34). The type of action mediated by IL-21 is presumably determined
by its biological context (24), depending on the specific activation state of the target cell as
well as the cytokine milieu.
In the BXSB-Yaa mouse model of systemic lupus erythematosus, serum IL-21 levels increased
with age, correlating with the severity of autoimmunity (24). Additionally, IL-10 levels
similarly increase (24). We now report that IL-21 is a potent regulator of IL-10 and demonstrate
that IL-10 production is decreased in IL-21R knockout (KO) mice but increased in IL-21
transgenic mice. These latter mice exhibit markedly defective immunoglobulin production in
response to specific immunization, consistent with a suppressive phenotype. We show that
IL-21 induces IL-10 expression in normal wild type T cells, including cells that are already
committed to Th1 or Tc1 differentiation. Moreover, TCR priming in the presence of IL-21
results in the accumulation of T cells with immunosuppressive activity that is dependent on
IL-10, and furthermore, immunosuppressive activity is unexpectedly observed in IL-21
transgenic mice, an effect that is largely mediated by IL-10.
Materials and Methods
Mice
C57BL/6 and Balb/c mice were from The Jackson Laboratory (Bar Harbor, ME). IL-10 KO
mice were from Taconic. IL-21R KO mice (22) on a C57BL/6 background (3 generations) and
IL-21 transgenic mice (24) on a mixed background (129xBl6) were previously described. Mice
lacking STAT3 expression in T cells (35) were generated by crossing Stat3 floxed mice (36)
with CD4-Cre recombinase transgenic mice. All experiments were performed under protocols
approved by the NHLBI Animal Care and Use Committee.
Th/Tc cell polarization
Splenic naive CD4+ or CD8+ T cells were isolated by positive selection with magnetic beads
(Miltenyi Biotec). Cells were cultured on plate-bound anti-CD3 (2 μg/ml) + anti-CD28 (1 μg/
ml) for 3 days either in the presence of IL-12 (10 ng/ml) + anti-IL-4 (11B11, 10 μg/ml) for
Th1 polarization or in the presence of IL-4 (100 U/ml) + anti-IFN-γ (XMG1.2, 10 μg/ml) for
Th2 polarization (antibodies from BD Biosciences). 50 ng/ml IL-21 (R&D Systems) was
included where indicated. Cells were expanded in IL-2 for 3 to 5 days and re-stimulated with
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PMA (10 ng/ml) + ionomycin (1 μM). For Th17/Tc17 differentiation, cells were cultured for
4 days on plate-bound anti-CD3 + anti-CD28 in the presence of TGFβ (2 ng/ml), IL-6 (10 ng/
ml), and both anti-IFN-γ and anti-IL-4. For intracellular cytokine production, cells were
stimulated for a total of 6 h with PMA + ionomycin, in the presence of Golgi stop for the last
4 h, fixed using the Cytofix/Cytoperm kit (BD Biosciences), and stained with antibodies to
IL-10 (JES5−16E3), IFN-γ (XMG1.2) (BD Biosciences) and IL-17A (EBiosciences). AE7, a
Th1 cell line (37), kindly provided by Dr. Ronald H. Schwartz, was activated by antigen in the
presence of APCs, and then expanded in IL-2, rested overnight before stimulation with PMA
+ ionomycin for 24 hrs.
RNA analysis
Total RNA was isolated using TRIzol (Invitrogen). First strand cDNAs were synthesized using
the Omniscript reverse transcription kit (Qiagen) and oligo-dT. Quantitative real time PCR
was performed on a 7900H sequence detection system (Applied Biosystems). Real time
primers and Taqman probes were from Applied Biosystems. RNA was normalized relative to
expression of Rpl7.
Retroviral transduction
Retroviral supernatants were produced from 293T cells co-transfected with pCL-Eco plus
either pRV-GFP or pStat3C-GFP (38), which encodes a constitutively-active STAT3, using
Lipofectamine (Invitrogen). One day later, cells were changed to complete RPMI-1640
medium and incubated at 32°C. Retrovirus-containing supernatant was harvested 48 and 72 h
after transfection. T cells were isolated from WT Balb/c mice and activated with 5 μg/ml plate
bound anti-CD3 + 1 μg/ml anti-CD28 for 24 h. Activated T cells were transduced with viral
supernatant in the presence of 8 μg/ml polybrene (Sigma) by spinning at 2,500 rpm for 45 min
at 30°C. Cells were further activated with 2 μg/ml anti-CD3 + 1 μg/ml anti-CD28, and a second
retroviral transduction was performed 24 h later. Cells were grown in complete RPMI medium
containing 100 U/ml IL-2 for 2 days, stimulated with 50 ng/ml IL-21 for 24 h, incubated with
PMA + ionomycin for 6 h and with Golgi stop for the last 4 h, fixed with Cytofix/Cytoperm,
and stained with PE-anti-IL-10 (BD Bioscience). Transduced (GFP+) cells that expressed IL-10
were quantified.
In vitro co-culture assay
OT-1 CD8+ T cells were labeled with CFSE (Molecular Probes) and stimulated with splenic
APC that had been depleted of T cells, irradiated (3000 rad), and pulsed with the SIINFEKL
peptide that is specific for the OT-1 TCR. These primed OT-1 cells were co-cultured at a ratio
of 2:1 with Th1 cells that had been primed in the presence or absence of 50 ng/ml IL-21 along
with anti-IL-10R (clone 1B1.3a; 10 μg/ml) or an isotype-matched control mAb (clone R3−34)
(BD Bioscience). Th1 cells were restimulated with anti-CD3 + anti-CD28 in either the presence
of absence of IL-21 on the day prior to the co-culture. Vα2+ CD8+ T cells were stained with
APC-anti-CD25 (3C7) (BD Bioscience) at 24 h, and CFSE dilution was monitored at days 2
and 3 after activation.
In vivo antibody and cytokine responses
IL-21 transgenic mice were immunized intraperitoneally with 100 μg ovalbumin emulsified
with Imject alum (Pierce). Ova-specific immunoglobulin levels were measured one week later,
as previously described (22).
Spolski et al. Page 3
J Immunol. Author manuscript; available in PMC 2010 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Results
IL-21 induces IL-10 production during the primary immune response
We previously observed high levels not only of IL-21 but also of IL-10 in BXSB-Yaa mice
(24), which develop systemic lupus erythematosus. To investigate whether IL-21 could
regulate the levels of IL-10, we first analyzed IL-10 production in CD4+ and CD8+ T cells
from either IL-21R KO mice (22) or IL-21 transgenic mice (24). Splenic T cells were stimulated
in vitro with anti-CD3 + anti-CD28, and levels of IL-10 production were measured. Levels of
IL-10 were markedly lower in cells from IL-21R KO mice than from WT mice, although IL-4
and IFN-γ levels were not affected (Fig. 1A). Conversely, IL-10 production was increased in
cells from IL-21 transgenic mice (Fig. 1B). Interestingly, IL-4 and IFN-γ production by the
IL-21 TG cells was also higher than from control cells (Fig. 1B).
To further investigate the ability of IL-21 to induce IL-10 expression, we next measured IL-10
mRNA levels in freshly isolated wild type CD4+ and CD8+ T cells. Stimulation of CD4+ T
cells with anti-CD3 + anti-CD28 induced IL-10 mRNA (Fig. 2A), but the addition of IL-21
increased the potency of this response at all time points examined (Fig. 2A). In contrast to its
effect on CD4+ T cells, anti-CD3 + anti-CD28 induced little IL-10 mRNA in CD8+ T cells,
but again the addition of IL-21 markedly increased IL-10 mRNA levels (Fig. 2B). Analysis of
secreted IL-10 protein levels in naive CD4+ and CD8+ T cells confirmed that IL-10 production
was induced by anti-CD3 + anti-CD28 in CD4+ T cells and was further enhanced by the addition
of IL-21, whereas anti-CD3 + anti-CD28 alone induced only a low level of IL-10 production
in CD8+ T cells, but the inclusion of IL-21 significantly induced IL-10 secretion (Fig. 2C).
Interestingly, IL-21 did not induce IL-10 expression in naïve CD4+ or CD8+ T cells (data not
shown). Three other γc family cytokines (IL-2, IL-7, IL-15) were evaluated either alone or in
combination with IL-21 for their ability to induce IL-10 in the primary response of CD4+ or
CD8+ T cells. Of these cytokines, only IL-21 significantly induced IL-10 (Suppl. Fig.1). This
is potentially explained by the fact that IL-2, IL-7, and IL-15 primarily activate STAT5 proteins
whereas IL-21 favors STAT3.
IL-21 induction of IL-10 is mediated by STAT3
Because IL-21 activates STAT3 (10,35,39), we next investigated whether STAT3 is required
for IL-21-induced IL-10 expression using conditional KO mice that lack expression of STAT3
in T cells (35,36). We compared IL-10 mRNA induction in WT and Stat3 KO CD4+ T cells
(Fig. 3A, left upper panel) and CD8+ T cells (Fig. 3A, right upper panel). As is evident, similar
levels of IL-10 were observed in both WT and Stat3 KO T cells that were stimulated only with
anti-CD3 (2 ug/ml) + anti-CD28 (1 ug/ml)(concentrations that induce maximal expression of
IL-10); however, the IL-21-boosted expression that was evident in WT cells was markedly
diminished in Stat3 KO T cells (Fig. 3A, upper panels). This indicates that there are at least
two mechanisms for inducing expression of the IL-10 gene: one that is TCR-dependent but
independent of STAT3 and another that is IL-21-dependent and mediated by STAT3. In
contrast to IL-10, IFN-γ mRNA induction by anti-CD3 + anti-CD28 was not diminished and
in fact was even augmented by IL-21 in Stat3 KO CD4+ (Fig. 3A, left lower panel) and
CD8+ (Fig. 3A, right lower panel) T cells. The importance of STAT3 for IL-21-mediated
induction of IL-10 expression was further evaluated by using a constitutively activated form
of STAT3 (38). As compared to a control retrovirus, transduction of a virus encoding
constitutively-activated STAT3 increased the number of IL-10-producing CD4+ and CD8+ T
cells, and this was further increased by the addition of IL-21 (Fig. 3B). This additional effect
of IL-21 may reflect its ability to also activate other signaling pathways, including, for example,
MAP kinase and PI 3-kinase coupled pathways (35).
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IL-21 induces IL-10 expression during polarization of Th1 and Tc1 cells
Because IL-10 is known to suppress inflammatory responses (4), we next investigated whether
IL-21 could influence IL-10 production during either Th1/Tc1 or Th2/Tc2 in vitro polarization.
Naive CD4+ or CD8+ T cells were cultured in Th1/Tc1 or Th2/Tc2 polarizing conditions (see
Methods) in the absence or presence of exogenous IL-21 for 7 days, and then re-stimulated
with PMA + ionomycin. IL-21 induced only a slight increase in IFN-γ in Th1 or Tc1 cells,
whereas a larger increase in IL-10 mRNA was observed in these cells (Fig. 4A, right panels).
Similarly, IL-21 increased IL-10 protein in Th1 and Tc1 cells (Fig. 4B). In contrast, in Th2 or
Tc2 cells, which express a high basal level of IL-10 mRNA and protein, IL-21 did not
significantly induce IL-10 expression (Fig. 4A and 4B). Flow cytometric analysis revealed that
stimulation of Th1 or Tc1 cells with IL-21 led to an increase in cells co-producing IL-10 and
IFN-γ (Fig. 4C, upper right quadrants) but not of cells producing only IL-10 (Fig. 4C, upper
left quadrants), indicating that the induction of IL-10 was occurring in already committed Th1
or Tc1 cells. Although IL-21 did not significantly increase the total amount of IL-10 mRNA
or protein produced by Tc2 cells, flow cytometry revealed that IL-21 led to an increase in the
number of Tc2 cells co-producing IL-10 and IFN-γ (Fig. 4C, upper right quadrants of Tc2 and
represented graphically in Suppl. Fig.2).
IL-21 upregulates IL-10 production during the induction of Th17/Tc17 polarized cells
Th17 cells can be generated in vitro by stimulating naive CD4+ T cells with anti-CD3 + anti-
CD28 in the presence of TGFβ and IL-6, and these conditions lead to the generation of
CD4+ T cells co-producing IL-17 and IL-10 (5). To determine whether IL-21 could also
influence the IL-10 production by Th17 cells, naive CD4+ or CD8+ T cells from WT or IL-21R
KO mice were similarly primed under Th17/Tc17 conditions for 4 d and intracellular cytokines
were evaluated (Fig. 5A). Priming of WT cells under these conditions led to the generation/
expansion of cells producing IL-10 alone or IL-17 alone as well as cells producing both
cytokines. T cells from IL-21R KO mice that were primed under Th17/Tc17 conditions
exhibited diminished numbers of cells producing both IL-10 and IL-17 and of cells producing
each individual cytokine.
Several groups have reported that IL-6 and IL-27 can induce IL-10 (5,40-42). We hypothesized
that this induction might be mediated, at least in part, via the induction of IL-21, given our
demonstration above that IL-21 can potently induce IL-10. We therefore investigated the
effects of IL-6 and IL-27 on the production of IL-21. CD4+ T cells were stimulated with anti-
CD3 + anti-CD28 alone or with TGFβ,TGFβ + IL-6, or TGFβ + IL-27 for 72 h, and levels of
secreted IL-21 were measured. IL-6 potently induced IL-21 (Fig. 5B), consistent with previous
observations (15-17). We also found that IL-27 induced IL-21 secretion by CD4+ T cells,
although less potently than did IL-6 (Fig. 5B). We next evaluated the contribution of IL-21
signaling to the induction of IL-10 by using IL-21R KO CD4+ T cells. Cells were stimulated
with anti-CD3 + anti-CD28 and TGFβ without or with the addition of IL-6, IL-21, or IL-27
for 4 days, and intracellular levels of IL-10 and IL-17 were then evaluated as described in the
Methods (Fig. 5C and 5D). All three cytokines substantially enhanced the production of IL-10
by WT cells (Fig. 5C, upper panels). As expected, the effect of IL-21 was not observed in
IL-21R KO T cells, but the number of IL-10 producing cells induced by IL-27 was also greatly
reduced in IL-21R KO T cells (Fig. 5C lower panels, and Fig. 5D), indicating that much of
the induction of IL-10 by IL-27 in fact occurred via the induction of IL-21. There was also a
partial decrease in IL-6-induced IL-10 expression in the IL-21R KO mice. When we compared
the effects of IL-21, IL-6, and IL-27 on the induction of IL-10 in T cells pre-activated with
anti-CD3 + anti-CD28 for 48 hrs but where TGFβ was not added, interestingly, IL-21 was
more potent than either IL-6 or IL-27 in its ability to induce IL-10 mRNA (Fig. 5E) and protein
(Fig. 5F) expression in both CD4+ and CD8+ T cells.
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IL-21 can induce IL-10 production in previously committed Th1, Tc1 or Tc17 cells
Above, we showed that IL-21 could increase IL-10 production when it was present at the time
of antigen stimulation under either neutral or polarizing conditions. We next investigated
whether IL-21 could also augment IL-10 expression in cells that were terminally committed
to lineages in which IL-10 production is greatly diminished. We first subjected CD8+ T cells
(which unlike CD4+ T cells do not produce IL-21) to three rounds of Tc1 or Tc17 polarization.
As shown in Fig. 6A, IL-21 enhanced TCR-induced IL-10 production in these already
committed cells (left set of bars in each panel). Interestingly, cells that were initially polarized
in the presence of IL-21 had a much higher response to TCR stimulation alone (compare the
solid bar in the right half of each panel to that in the left half of each panel).
We next investigated whether IL-21 could induce IL-10 production even in a Th1 committed
cell line, AE7. Although PMA + ionomycin alone induced relatively little IL-10 in this cell
line, the addition of IL-21 significantly increased the amount of IL-10 secreted protein (Fig.
6B). In cells treated with PMA + ionomycin + IL-2, which is required for long-term viability
of these cells, IL-21 induced approximately 4-fold more IL-10 than in cells not receiving the
IL-21. Although the IL-10 locus is not normally transcriptionally active in these committed
lineages (43), our results indicate that even in this context, IL-21 could augment IL-10 mRNA
levels.
Th1 cells primed in the presence of IL-21 exhibit a marked IL-10-mediated inhibitory effect
on antigen-induced IL-2Rα expression and cell-cycle progression
IL-10-producing cells can inhibit the proliferation and/or activation of other cellular subsets
(3). We therefore examined the functional consequences of IL-21-induced expression of IL-10
using TCR transgenic OT-1 CD8+ T cells that were activated using splenic APC that had been
pulsed with the SIINFEKL peptide, which is recognized by the OT-1 TCR. As expected,
activated OT-1 cells exhibited high expression of the IL-2 receptor α chain (CD25) (Fig. 7A,
left upper panel). The addition of Th1 cells modestly decreased this expression (Fig. 7A, middle
upper panel), but Th1 cells polarized in the presence of IL-21 had an even greater inhibitory
effect (Fig. 7A, right upper panel). Analogous inhibitory effects on cell cycle progression were
observed when CFSE dilution was examined, with IL-21-primed Th1 cells having a greater
inhibitory effect on CFSE dilution than Th1 cells not exposed to IL-21 (Fig. 7B). The slight
effect of Th1 cells polarized in the absence of IL-21 may reflect competitive growth effects
resulting from the addition of these cells in a 2:1 CD8:CD4 ratio. The addition of an antibody
to IL-10R partially reversed the inhibition induced by priming with IL-21 (Fig. 7A, lower right
panel versus upper right panel). Consistent with this finding, as compared to WT Th1 cells,
IL-10 KO Th1 cells primed with IL-21 did not inhibit OT-1 activation as assessed by IL-2Rα
(CD25) expression (Fig. 7C, compare lower right to upper right panel), confirming that the
suppressive effect of IL-21 was indeed dependent on IL-10. The addition of IL-10 to OT-1
cells primed with peptide/APC also diminished the induction of CD25, confirming that IL-10
can mediate this suppressive effect independent of the presence of T helper cells (Suppl. Fig.
3).
IL-21 suppression of in vivo immunoglobulin induction is mediated in part by IL-10
Even though IL-21 induces terminal differentiation of B cells and is required for a normal
immune response (22,24), the elevated levels of IL-10 produced by IL-21 transgenic cells
suggested that these mice might unexpectedly exhibit an immunosuppressive phenotype in the
context of an immune response. To investigate this possibility, we immunized the mice
intraperitoneally with ovalbumin and measured primary serum immunoglobulin responses at
day 7. As shown in Fig. 8, ovalbumin-specific IgM, IgG1, IgG2a, and IgG2b were substantially
lower in the IL-21 transgenic mice (TG/WT) than in wild-type littermates (WT). To determine
whether this decreased response was a result of IL-21-mediated IL-10 induction, the IL-21
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transgenic mice were crossed onto the IL-10 KO mouse background (TG/KO). These mice had
similar OVA-specific IgM and IgG2b responses to those of WT mice, showing that deleting
IL-10 reversed the suppressive effect of IL-21 transgenic expression on production of these
immunoglobulins. OVA-specific IgG1 and IgG2a responses were also reversed in the absence
of IL-10, albeit only partially. Thus, we show that IL-21 can suppress antigen-induced
immunoglobulin production and that IL-10 production plays an important role in mediating
this immunosuppressive effect of IL-21. The fact that the IgG1 and IgG2a effect were only
partially reversed on the IL-10 KO background suggests that other factors may also contribute
to the immunosuppressive effects of IL-21.
Discussion
IL-21 is a pleiotropic cytokine with an array of actions on T, B, NK, and myeloid cells (11).
IL-10 is produced by multiple cell types, and like IL-21, it has pleiotropic effects on multiple
lineages. Among its actions, IL-10 has immunosuppressive properties related to its direct
effects on antigen-presenting cells and its ability to inhibit the production of multiple cytokines
and chemokines (4,44), but it also has stimulatory effects, such as its abilities to augment the
number of CD8+ T cells during a primary response (45) and the proliferation of B cells activated
via the B-cell receptor and costimulatory signals (4,44).
We have now shown that IL-21 increases IL-10 expression in TCR-stimulated naive CD4+ and
CD8+ T cells and potently induces IL-10 in pre-activated T cells. A previous study showed
that IL-21 could augment anti-CD40-induced B cell production of IL-10, but the total
production of IL-10 was small and was associated with a 4−5 fold expansion of B cells (46).
Our results in T cells are direct and not dependent on proliferative amplification of target cells.
IL-21 has also been shown to augment IL-10 production in long-term NK cell cultures that
were stimulated with either IL-2 or IL-15 and this augmentation was accompanied by an
increased functional maturation of NK cells (47). Thus, although IL-21 augments IL-10
production in B cells and NK cells, this production correlated with positive effects on
differentiation or proliferation rather than with immunosuppressive effects as we observed in
T cells. Interestingly, although we show that IL-21 can induce IL-10 in several different T
helper lineages, T follicular helper cells isolated from immunized mice were shown to produce
IL-21 but did not produce IL-10 (25). The absence of IL-10 production by these cells may be
important in germinal center proliferation and expansion of memory B cells, as IL-10 has been
found to inhibit memory B cell proliferation and favor differentiation to plasma cells (48).
These results identify a novel mechanism by which IL-10 production can be induced and
amplified in both naive and activated T cells. Although IL-6 has been shown to directly induce
IL-10 in naive CD4+ T cells (5,41), this induction is partially dependent on the intermediate
induction of IL-21, which can then either directly induce IL-10 production or further amplify
the IL-6-induced IL-10 production. Although both IL-6 and IL-21 induce IL-10 in a STAT3-
mediated manner during the primary induction of naive T cells, there are differences in the
ability of these two cytokines to induce IL-10 in already activated T cells, suggesting potential
differences in downstream signaling events via these cytokines. Moreover, we show that IL-27-
induced IL-10 production in naive CD4+ T cells stimulated via the TCR is largely dependent
on the intermediate induction of IL-21, providing a likely mechanism for the observation that
IL-27 suppresses autoimmune inflammation via IL-10 (40). Interestingly, as compared to IL-6
and IL-27, in preactivated T cells, IL-21 is the most potent inducer of IL-10 production.
In cells polarized using Th17 conditions (TGFβ + IL-6), there was an increase in cells that
produce only IL-10 and in cells producing both IL-10 and IL-17, but each of these populations
was diminished when IL-21R KO cells were used. Recently, it was shown that Th17
polarization results in the generation of cells containing two major subpopulations that
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separately produce either IL-21 or IL-17 (49). IL-10 was produced by each of these
subpopulations but again levels were diminished when these cells were derived from IL-21R
KO mice, indicating a key role for IL-21 in the production of IL-10.
The functionality of the IL-21/IL-10 connection was demonstrated by the augmented inhibitory
activity of Th1 cells primed with IL-21; the inhibitory activity of IL-21 correlated with its
induction of IL-10 and was diminished by an antibody to IL-10R. Furthermore, when IL-10
KO Th1 cells were primed with IL-21, no inhibitory activity was observed, establishing a
critical role for IL-10 in mediating the immunosuppressive activities of IL-21. IL-10 is
produced by multiple lineages that function as suppressors, including natural Treg cells (3).
However, we have found no differences in either the number or the suppressive activity of Treg
cells in IL-21R KO mice. The induction of IL-10 by IL-21 in already differentiated effector T
cell populations may be of importance in the control of inflammation, as IL-10 production by
IFNγ-producing CD4+ T cells has been shown to play a major role in host protection from
inflammation in several infectious disease models (6,50). We have examined the responses of
IL-21R KO mice to Toxoplasma gondii and found no difference in either the degree of infection
or in the production of IFN-γ/IL-10 double producer cells (unpublished observations),
indicating that there are redundant pathways controlling the production of IL-10.
Our demonstration that transgenic expression of IL-21 leads to suppression of in vivo
immunoglobulin responses underscores the complexity of B cell responses to IL-21. We
previously demonstrated that IL-21 plays a critical positive role in Ig responses (22) and in
plasma cell differentiation (24), but it can also mediate B cell apoptosis when the appropriate
costimulation is absent (32,33), suggesting the importance of context for the IL-21 signal.
Although young (4−8 week old) IL-21 transgenic mice have higher serum Ig levels, these levels
decline with age (4 months and older) (unpublished observations), suggesting that the effects
of chronic IL-21 activity may alter the ability of this cytokine to function as a positive regulator
of Ig production.
Importantly, our demonstration that IL-21 induces IL-10 provides an explanation for the
elevated IL-10 in the BXSB-Yaa mouse model of systemic lupus erythematosus. In humans
with SLE, serum levels of IL-10 are also increased (51,52) and increased IL-21 has also been
observed in a substantial fraction of humans with SLE (53). Although it is unclear whether the
production of IL-10 in human SLE is a mediator of this disease or a suppressive response that
limits disease activity, it is interesting that diminished disease severity resulted from the
administration of IL-10 with an AAV gene delivery system in the NZM2410 mouse model of
lupus (54), whereas more severe disease occurred in MRL-lpr mice on the IL-10 KO
background (55). These results support the idea that the production of IL-10 in response to
IL-21 may serve to suppress disease activity. Like the BXSB-Yaa mice, MRL-lpr mice also
produce a higher level of IL-21 (56).
In summary, we have shown that IL-21 is a potent inducer of IL-10 and that it can mediate
immunosuppressive effects. This indicates a new function for IL-21 that was unanticipated
given that IL-21 is required for normal immunoglobulin production and is implicated in the
development of autoimmunity. We also have identified IL-21 as a critical mediator of the
induction of IL-10 by IL-27, indicating a broader role for IL-21 than previously anticipated.
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Figure 1.
IL-21 induces IL-10 expression. (A and B) Splenic T cells from either IL-21R KO mice and
their littermate controls (A) or from IL-21 TG mice and their littermate controls (B) were
purified by negative selection and stimulated in vitro with anti-CD3 (2 ug/ml) + anti-CD28 (1
ug/ml) for 48 h. Secreted IL-10, IL-4, and IFNγ were measured by ELISA using specific kits
(BD PharMingen). Shown is an experiment representative of three individual experiments. *P
< 0.01; **P < 0.001. The genetic backgrounds for the IL-21R KO mice and IL-21 transgenic
mice differ (see Methods).
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Figure 2.
IL-21 induces IL-10 mRNA in CD4+ and CD8+ T cells. (A and B) Splenic CD4+ or CD8+ T
cells from Balb/c mice were stimulated with anti-CD3 (2 ug/ml) + anti-CD28 (1 ug/ml) without
or with IL-21 for the indicated times and IL-10 mRNA levels measured by real-time PCR. The
control refers to cells not exposed to either anti-CD3+ anti-CD28 or to IL-21. IL-21 alone did
not induce IL-10 mRNA above control levels in either CD4+ or CD8+ T cells (not shown).
(C) Naive CD4+ or CD8+ T cells were stimulated with anti-CD3 + anti-CD28 in the absence
or presence of IL-21 for 48 h, at which point culture supernatants were assayed for IL-10 by
ELISA (BD Pharmingen). Data are representative of three individual experiments. *P < 0.05;
**P < 0.01.
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Figure 3.
IL-21-induced expression of IL-10 is mediated by STAT3. (A) IL-21-mediated induction of
IL-10 is diminished in CD4+ and CD8+ splenic T cells from Stat3 KO mice (upper panels),
whereas IFN-γ is not diminished (lower panels). CD4+ and CD8+ splenic T cells were isolated
from Stat3 KO mice or WT littermates and stimulated with anti-CD3 (2 ug/ml) + anti-CD28
(1 ug/ml) in the absence or presence of IL-21 for 6 h. Relative IL-10 and IFN-γ mRNA levels
were quantified by real-time PCR. *P < 0.05; **P<0.01 (B) Constitutively activated STAT3
expression augments basal and IL-21-induced IL-10 protein expression. CD4+ and CD8+ T
cells from Balb/c mice were transduced with a retrovirus encoding a constitutively activated
form of STAT3. Cells were stimulated overnight with anti-CD3 (2 ug/ml) + anti-CD28 (1 ug/
ml) without or with IL-21 and stained intracellularly with antibodies to IL-10. FACS analysis
of gated GFP-positive CD4+ or CD8+ T cells is shown. Data shown are representative of three
individual experiments.
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Figure 4.
IL-21 induces IL-10 mRNA and protein expression in Th1 and Tc1 cells. (A and B) Naive
CD4+ or CD8+ T cells were polarized under either Th1/Tc1 or Th2/Tc2 conditions in the
absence or presence of IL-21 and then expanded in IL-2. In (A), polarized cells were then
stimulated with PMA + ionomycin for 6 h and relative levels of IFN-γ, IL-4, and IL-10 mRNA
were quantified by real-time PCR. In (B), Th1/Tc1 and Th2/Tc2 polarized cells were re-
stimulated with anti-CD3 + anti-CD28 for 48 h in the absence or presence of IL-21, and levels
of IL-10 secreted in culture supernatants were measured by ELISA. Statistically significant
differences, when present, are indicated by asterisks: *P < 0.05; **P < 0.01; ***P < 0.001.
(C) Th1/Tc1 and Th2/Tc2 cells that had been polarized either in the absence or presence of
IL-21 were re-stimulated for 6 h with PMA + ionomycin in the presence of Golgi stop for the
last 4 h. Intracellular levels of IL-10 and IFN-γ were assessed by flow cytometry. The quadrants
were determined based on staining with isotype control antibodies. Data shown are
representative of three individual experiments.
Spolski et al. Page 16
J Immunol. Author manuscript; available in PMC 2010 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5.
IL-21 controls expression of IL-10 in Th17/Tc17 primary cells and is required for normal
induction of IL-10 by IL-6 or IL-27. (A) Naive CD4+ or CD8+ T cells from WT or IL-21R KO
mice were polarized in vitro in the presence of TGFβ + IL-6 for 4 days and re-stimulated for
6 h with PMA + ionomycin in the presence of Golgi stop for the last 4 h. Intracellular levels
of IL-10 and IL-17 were assessed by flow cytometry. The quadrants were determined based
on staining with isotype control antibodies. (B) WT CD4+ T cells were stimulated under neutral
conditions with anti-CD3 + anti-CD28 in the presence or absence of TGFβ and IL-6 or IL-27
for 4 days, at which time culture supernatants were assayed by ELISA for IL-21. (C) CD4+ T
cells from either WT or IL-21R KO mice were stimulated with anti-CD3 + anti-CD28 + anti-
IFNγ + anti-IL-4 in the presence of TGFβ with either IL-6, IL-21, or IL-27 for 4 days and then
re-stimulated for 6 h with PMA + ionomycin in the presence of Golgi stop for the last 4 h.
Intracellular levels of IL-10 and IL-17 were assessed by flow cytometry. (D) The percentage
of IL-10 positive cells in (c) are represented in a bar graph. (E) CD4+ and CD8+ T cells were
pre-activated with anti-CD3 + anti-CD28 for 48 h, washed and rested overnight, and were re-
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stimulated without or with IL-6, IL-21 or IL-27 for 6 h. RNA was then isolated and relative
IL-10 mRNA levels quantified by real-time PCR. (F) Parallel culture supernatants were
assayed at 48 h for IL-10 by ELISA. *P<0.01; **P<0.05.
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Figure 6.
IL-21 augments IL-10 expression even in committed Tc1 or Tc17 primary cells and in Th1
committed AE7 cells. (A) CD8+ T cells were subjected to three rounds of polarization under
either Tc1 or Tc17 conditions in either the absence or presence of IL-21 and were then
stimulated with or without anti-CD3/CD28 in either the absence or presence of IL-21 for 24
h, at which point IL-10 levels were measured in culture supernatants. (B) AE7 cells were TCR
stimulated and were then expanded in IL-2, rested overnight and were then re-stimulated with
PMA + ionomycin in either the presence or absence of IL-21 and IL-2. Culture supernatants
were assayed by ELISA at 24 h for IL-10 and IFN-γ. Data shown are representative of three
separate experiments. *P < 0.05.
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Figure 7.
Th1 cells polarized in the presence of IL-21 inhibit the activation of naive CD8+ T cells, and
this inhibition is IL-10-dependent. Naive OT-1 cells were activated with peptide/APC in the
absence or presence of Th1 cells that were primed in the presence or absence of IL-21. (A)
CD25 surface expression on gated Vα2+ OT-1 cells was measured by flow cytometry at 48 h
in cells treated either with a control Ab (upper panels) or anti-IL-10R (lower panels). MFIs are
indicated in each profile. (B) Proliferation of OT-1 cells was assessed by CFSE dilution at 48
h after peptide/APC stimulation. Shown is the effect of the addition of Th1 cells primed in the
absence vs. presence of IL-21. The percentage of cells in the indicated region is shown. MFIs
were 96, 237, and 351 for OT-1, OT-1 + Th1, and OT-1 + Th1/IL-21, respectively. These
proliferation assays were performed in the absence of exogenous IL-2. (C) CD25 surface
expression on OT-1 cells from WT mice (upper two panels) or IL-10 KO mice (lower two
panels) was measured at 48 h without co-culture (left panel) or after co-culture with Th1 cells
(middle panels) or Th1 cells polarized with IL-21 (right panels). MFIs are indicated in each
profile. Shown is an experiment representative of three individual experiments.
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Figure 8.
IL-21 transgenic mice exhibit diminished production of specific antibody in response to
primary immunization with ovalbumin, and this inhibition is partially dependent on the
presence of IL-10. IL-21 transgenic mice and non-transgenic littermates on IL-10 KO and WT
backgrounds were immunized i.p. with 100 ug ovalbumin in alum. At day 7 after primary
immunization, serum levels of OVA-specific immunoglobulin isotypes were assessed by
ELISA. Data are mean ± SEM from three experiments (2−4 animals per experiment). Statistical
significance was determined using Student's t test. *The statistical difference between TG/WT
and TG/IL-10 KO was P < 0.001 for IgM, P < 0.002 for IgG1, P < 0.02 for IgG2a, and ) <
0.009 for IgG2b.
Spolski et al. Page 21
J Immunol. Author manuscript; available in PMC 2010 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
